Pharma Business - June 27, 2019
Sobi lays off 90 employees
Swedish Orphan Biovitrum has announced that it intends to discontinue discovery/early research and partner R&D programmes outside its core focus areas. The new focus of the R&D organisation is expected to lead to annual savings of SEK 200–300 M on a full-year basis in 2020, which will increase the company’s financial flexibility to reallocate future […]
Acquisition - June 12, 2019
Sobi acquires emapalumab and related assets from Novimmune
Swedish Orphan Biovitrum (Sobi) has signed an agreement to acquire, from Novimmune’s shareholders, a newly established company owning emapalumab and related assets. It has also announced a reorganization to increase the focus of research & development resources to support its two core therapeutic areas: Haematology and Immunology. The acquisition gives Sobi access to world-class R&D capabilities […]
Drug Development Pharma - February 8, 2018
New data from Sobi
Swedish Orphan Biovitrum will present new evidence at the upcoming 11th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), in Madrid, Spain, 7-9 February 2018. These data mark the company´s commitment to elevate haemophilia management and expand the available clinical evidence for Elocta and Alprolix, demonstrating the need to rethink the current concept […]
Clinical Trials - January 23, 2018
FDA accepts Sobi’s IND application
Swedish Orphan Biovitrum announces that the FDA has issued a Study may proceed letter for the first study in humans, thereby accepting the investigational new drug (IND) application for the drug candidate SOBI003. In addition, SOBI003 was granted Fast Track status by the FDA. SOBI003 is a chemically modified human recombinant sulfamidase for the treatment of mucopolysaccharidosis type IIIA […]
New Market - October 26, 2017
Sobi ‘s Alprolix approved in Saudi Arabia
Swedish Orphan Biovitrum announces that the Saudi Food & Drug Authority in the Kingdom of Saudi Arabia has approved Alprolix (eftrenonacog alfa), for the treatment of haemophilia B. Alprolix is the first extended half-life and recombinant factor IX Fc fusion protein therapy approved for the treatment of haemophilia B in Saudi Arabia. “We are very pleased Alprolix is […]
Pharma Business - June 1, 2017
Sobi discloses payments to healthcare professionals and healthcare organisations
Swedish Orphan Biovitrum announces that the company has made all payments and transfers of value to healthcare professionals and organisations from 2016 publicly available*, including sponsorships to attend meetings, grants and donations, speaker fees, consultancy and advisory boards in accordance with the European Federation of Pharmaceutical Industries and Associations (EFPIA) Disclosure Code. The information is […]
